Consistent with our data, a study of 32,356 patients treated for any gynaecological cancer with PARP inhibitors showed that the rate of secondary MDS/AML in the total population was almost 1% but was nine times higher in ovarian cancer patients. This evidence concerns the gene PARP1 and myelodysplastic syndrome.